Form 4: Charles River Laboratories CEO James C. Foster Reports Stock Sale

James C. Foster, Chairman, President, and CEO of Charles River Laboratories, reported the sale of 25,000 shares of common stock on August 1, 2024.

Summary

• James C. Foster, the Chairman, President, and CEO of Charles River Laboratories International, Inc., filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• On August 1, 2024, Foster sold 25,000 shares of common stock at a price of $250 per share.
• This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 26, 2024.
• Foster's direct holdings after the sale amount to 188,251 shares.
• He also holds shares indirectly through various grantor retained annuity trusts (GRATs) and trusts, as well as shares held by his spouse.
• There was a transfer of 10,207 shares from the 2023 GRAT to direct holdings on June 5, 2024.
• Additionally, 20,000 shares were transferred from direct holdings to the 2024 GRAT on June 6, 2024.
• The report also corrects a previous error, reducing the reported holdings by 110 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of a stock sale under a pre-arranged trading plan. It doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and potential future performance of the company.

Stakeholder Impact

• The stock sale by the CEO may be perceived neutrally by shareholders as it was executed under a pre-arranged trading plan.

Key Dates